#1698348 Gender and Racial Disparities in the Utilization of GLP-1 Analogues in Obese Patients: A TriNetX Database Analysis

This study aimed to identify gender and racial disparities in the utilization of Glucagon-like peptide-1 (GLP-1) analogues among obese patients with a Body Mass Index (BMI) of 30 to 49. A retrospective cohort study was conducted using the TriNetX database, which initially included 97,198,703 patients aged 18 and older. A total of 314,610 patients were selected based on their BMI (30-49) and treatment with GLP-1 analogues in the last five years. The study analyzed the distribution of GLP-1 analogue use across different genders and racial groups. The average age at index was 55.4 ± 13.6 years. Women constituted the majority of the cohort, representing 60% (188,798 patients), while men accounted for 31% (98,045 patients), and gender was unknown for 9% (27,767 patients). Racial distribution revealed that Whites were the majority at 62% (195,872 patients), followed by Black or African Americans at 18% (56,631 patients), Asians at 2% (6,216 patients), Native Hawaiians or other Pacific Islanders at 1% (2,505 patients), and American Indians or Alaska Natives at 1% (1,228 patients). This study highlights significant gender and racial disparities in the use of GLP-1 analogues among obese patients. Women are more likely to be treated with these agents compared to men, and there is a notable predominance in the utilization among White individuals compared to other racial groups. These findings underscore the need for targeted efforts to understand and address the underlying causes of these disparities to ensure equitable access to obesity treatments.